Clinical Trials

Find a Trial

Trial Results

15 protocol(s) meet the specified criteria
EA8143OPEN TO ACCRUAL
A Phase 3 Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
GU14-188OPEN TO ACCRUAL
Phase Ib/II Study of Neoadjuvant Pembrolizumab (MK-3475) with Gemcitabine-Cisplatin (cisplatin eligible) or Gemcitabine (cisplatin-ineligible) in Subjects with T2-4aN0M0 Urothelial Cancer
GU17-289OPEN TO ACCRUAL
A Phase II Randomized, Open label Study of High Dose Interleukin 2 vs High Dose Interleukin 2 plus Entinostat in Untreated Advanced Renal Cell Carcinoma
IUCRO-0042OPEN TO ACCRUAL
Blood Drawing for Study of Peripheral Blood T-Lymphocytes and Other Parameters in patients with Metastatic Melanoma and Renal Cell Cancer with Spontaneous Regression
IUCRO-0049OPEN TO ACCRUAL
Immunologic, Genetic, Molecular, and Pathological Correlates with Clinical and Treatment Outcome in Patients with Renal Cell Carcinoma
IUCRO-0459OPEN TO ACCRUAL
Investigating A Novel Modifiable Factor Affecting Renal Function After Partial Nephrectomy: Cortical Renorrhaphy
IUCRO-0474OPEN TO ACCRUAL
Evaluation Of A Laparoscopic High Intensity Focused Ultrasound Probe For The Ablation Of Small Renal Masses
IUSCC-0551OPEN TO ACCRUAL
A Phase I/Ib, Open Label, Dose Finding Study to Evaluate Safety, Pharmacodynamics and Efficacy of Pembrolizumab (MK-3475) in Combination with Vorinostat in Patients with Advanced Renal or Urothelial Cell Carcinoma
IUSCC-0564OPEN TO ACCRUAL
Kidney Cancer Services (KCS) Registry and Bio-Bank
IUSCC-0584OPEN TO ACCRUAL
COLLECTION OF SPECIMENS AND CLINICAL DATA TO CREATE A BIOREPOSITORY FOR THE GENITOURINARY ONCOLOGY PROGRAM
IUSCC-0615OPEN TO ACCRUAL
Pilot Ex-Vivo Investigation of an Experimental Beta Probe for Assessment and Guidance of Prostate Cancer Resection
IUSCC-0645OPEN TO ACCRUAL
Description of Cardiotoxicity Associated with Sunitinib in Renal Cell Carcinoma
NKTR16-214-02OPEN TO ACCRUAL
A PHASE 1/2, OPEN-LABEL, MULTICENTER, DOSE ESCALATION AND DOSE EXPANSION STUDY OF NKTR-214 AND NIVOLUMAB IN PATIENTS WITH SELECT LOCALLY ADVANCED OR METASTATIC SOLID TUMOR MALIGNANCIES
PHO-COG-FALLON-AREN03B2OPEN TO ACCRUAL
Renal Tumors Classification, Biology, and Banking Study
S1500OPEN TO ACCRUAL
A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)